# Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

> **NCT05657613** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 60 (actual)

## Conditions studied

- Drug Interactions

## Interventions

- **DRUG:** CYP450 Cocktail and Transporter Substrates with Pacritinib
- **DRUG:** Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib
- **DRUG:** Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib

## Key facts

- **NCT ID:** NCT05657613
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2023-06-08
- **Final completion:** 2023-06-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657613, "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05657613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*